In the 6‐month pivotal Phase 3 (VANGUARD) study (NCT04656418), patients aged ≥ 12 years with HAE with C1INH deficiency or dysfunction and an average attack rate of ≥ 3 attacks in the 3 months preceding study initiation were randomised (3:2) to receive garadacimab 200 mg subcutaneous once monthly after an initial 400 mg loading dose (n = 39) or volume‐matched placebo (n = 25). The gene discussed is SERPING1; the disease is hereditary angioedema.